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Abstract
Patients with pancreatic cancer have dismal prognoses, and novel therapies are urgently needed. Mutations of the
KRAS oncogene occur frequently in pancreatic cancer and represent an attractive target. Direct targeting of the
predominant KRAS pathways have been challenging and research into therapeutic strategies have been now
refocused on pathways downstream of KRAS, phosphoinositide 3-kinase (PI3K) and mitogen-activated protein
kinase (MAPK [MEK]). We hypothesized that concurrent inhibition of the PI3K and MEK pathways would result in
synergistic antitumor activity, as it would circumvent the compensatory feedback loop between the two pathways. We
investigated the combined effect of the PI3K inhibitor, GDC0941, and the MEK inhibitor, AZD6244, on cell viability,
apoptosis and cell signaling in a panel of pancreatic cancer cell lines. An in vivo analysis was conducted on
pancreatic cancer xenografts. While BxPC-3 (KRAS wild type) and MIA PaCa-2 (KRAS mutated) cell lines were
sensitive to GDC0941 and AZD6244 as single agents, synergistic inhibition of tumor cell growth and induction of
apoptosis were observed in both cell lines when the two drugs were combined. Interestingly, phosphorylation of the
cap-dependent translational components, 4E-binding protein (p-4E-BP1) and S6 was found to be closely associated
with sensitivity to GDC0941 and AZD6244. In BxPC-3 cell xenografts, survival differences were observed between
the control and the AZD6244, GDC0941, and combination groups. Our study provides the rationale for concurrent
targeting of the PI3K and MEK pathways, regardless of KRAS status, and suggests that phosphorylation of 4E-
BP1and S6 can serve as a predictive biomarker for response to treatment.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer-
related deaths in men and women in the United States. An
estimated 43,140 people were diagnosed with and 36,800 died
of pancreatic cancer in 2013 [1]. The lack of screening
methods and effective therapeutic agents make detecting and
treating pancreatic cancer a difficult problem. While targeted
agents have become the mainstream for other types of cancer,
at present, only the epidermal growth factor receptor inhibitor
erlotinib has gained approval from the Food and Drug
Administration for the treatment of pancreatic cancer [2].
Unfortunately, the clinical utility of erlotinib is largely limited due
to its rather modest clinical benefit, reflecting a continued
urgency to develop targeted agents in pancreatic cancer.
The presence of a KRAS mutation is seen in 30% of
premalignant lesions [3] and in up to 90% of pancreatic cancer
tumor specimens [4], suggesting that the KRAS mutation is the
predominant known feature of pancreatic cancer molecular
pathogenesis. KRAS is a GTPase, and it converts extracellular
signals into intracellular signals by cycling between the active
(RAS-GTP) and inactive (RAS-GDP) states. Mutated KRAS
results in constant activation of the RAS pathway by locking
RAS into the active GTP-binding state and further triggering
multiple downstream signaling pathways including cell
proliferation, apoptosis, differentiation, and survival [5]. Direct
targeting of KRAS has not been successful in patients with
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pancreatic cancer [6], so current research efforts have
refocused on two downstream pathways, the
phosphatidylinositol 3-kinase (PI3K)/AKT pathway [7] and the
RAF/MEK pathway [8,9].
Because cell signaling networks are complex, simply
blocking one mediator is unlikely to result in a significant
clinical response, unless the genetic alternation renders the
targeted “effector” to be an oncologically driven event. This is
hardly the case in KRAS downstream pathways, illustrated by
the exceedingly low incidence of PIK3CA or BRAF mutations in
pancreatic tumors [10]. Therefore, it has been hypothesized
that concurrent blockade in two parallel pathways such as PI3K
and MEK will significantly increase the chance for success in
achieving a clinically relevant response. Indeed, synergistic
anti-tumor effects have been observed when PI3K/AKT and
MEK pathways are both inhibited in preclinical tumor models
[11], including a KRAS mutated lung cancer model [12].
GDC0941 is an oral agent developed to inhibit all four class І
PI3K isoforms [13]. It has dose-dependent anti-tumor activity
against glioblastoma and human ovarian cancer xenografts
[14]. GDC0941 has shown promising anti-tumor activity in the
preclinical setting, and it is currently being tested in early phase
clinical trials [14]. AZD6244 is a potent, selective secondary
generation MEK1/2 inhibitor, which inhibits MAPK/ERK in an
ATP-uncompetitive fashion [15]. Along with other MEK
inhibitors, AZD6422 is currently in early phase clinical trials
[16-18]. Preclinical evaluations of combining a PI3K/AKT
inhibitor and a MEK inhibitor in pancreatic cancer are emerging
[19], and our study confirms that a synergistic effect occurs
when blocking these two pathways. Moreover, we have further
illustrated that the benefit of concurrent blockade is not KRAS
genotype limited. Additionally, our study shows that the
translation process, in particular, activation of 4E-binding
protein 1 (4E-BP1) and S6 seems to be associated with the
pancreatic cancer cells’ phenotypic response toward the
inhibitors.
Materials and Methods
Cell Culture and Inhibitors
Pancreatic cancer cell lines, BxPC-3 (KRAS wild type), MIA
PaCa-2 (KRAS mutant), PANC-1 (KRAS mutant) and Capan-2
(KRAS mutant) were obtained from American Type Culture
Collection (Manassas, VA, USA) and cultured in a growth
medium of either DMEM (PANC-1, MIA PaCa-2), RPMI-1640
(BxPC-3) or McCoy’s 5A medium (Capan-2) supplemented
with 10% fetal bovine serum, 100 units/ml penicillin, 100 µg/ml
streptomycin and 1mM sodium pyruvate at 37°C in a humidified
atmosphere containing 5% CO2. The PI3K inhibitor GDC0941
and MEK inhibitor AZD6244 were purchased from Selleck
Chemicals LLC (Houston, TX, USA) and dissolved in
dimethylsulfoxide. Both inhibitors were stored at -20°C.
Cell Viability Assay
Pancreatic cancer cells lines were seeded at a density of
3,000 cells per well in a 96-well microtiter plate in growth
medium and allowed to adhere overnight. GDC0941 or
AZD6244 dose-response was determined by treating the
pancreatic cancer cells lines with 5 concentrations of the drugs
based on a 10-fold dilution series. Cell viability was assessed
72 hours later by Alamar Blue (Invitrogen, NY, USA) (570λ Ex/
580λEm) with a fluorescent microplate reader, and expressed as
a percentage of drug-treated cells relative to control (no drug)
cells. Data were analyzed using GraphPad Prism 5 software
(GraphPad Software, Inc. San Diego, CA, USA), and the dose
response curve was used to calculate the concentration of drug
resulting in 50% inhibition of cell viability (IC50) using a four
parametric logistical model. All assays were repeated five
times.
For drug combination studies, the synergistic effect was
assessed by the combination index (CI), according to the
method of Chou & Talalay wherein synergism is defined as CI
< 1, while antagonism is CI > 1, and an additive effect is
considered as CI = 1 [20]. Cell lines were treated with
GDC0941, AZD6244 or a combination of GDC0941 and
AZD6244, and the number of viable cells was used to calculate
the CI values using CalcuSyn software (Biosoft, Cambridge,
United Kingdom).
Apoptosis Assay
Approximately 2×105 cells were seeded in 6-well plates for
24 hours. Cells were then treated with various concentrations
of GDC0941, AZD6244 or a combination of GDC0941 and
AZD6244 for 72 hours. Cells were harvested with 0.25%
trypsin, washed with phosphate buffered saline (PBS), and
collected together by centrifugation. The cells were then
stained with the Annexin V-FITC and PI solution (BD
Biosciences, San Diego, CA, USA) according to the
manufacturer’s instructions and were analyzed with a FAC
scan flow cytometer (Becton Dickinson, San Diego, CA, USA).
All experiments were performed in triplicate.
Western Blot Assay
Cells were seeded in 6-well plates for in vitro analyses.
When cells became 70-80% confluent, they were incubated
with GDC0941, AZD6244 or both GDC0941 and AZD6244 for
24 hours. Then the cells were washed with cold PBS, and
lysed in RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl,
1% Triton x-100, 1% sodium deoxycholate, 0.1%, SDS, 1 mM
EDTA, protease inhibitors). The supernatants were collected
after sonification and centrifugation, and equal amounts of
proteins were electrophoresed through 4-12% Bis-Tris Gels
and transferred to nitrocellulose membranes (Invitrogen,
Carlsbad, CA, USA). Membranes were blocked with 5% non-fat
milk following overnight incubation with the appropriate primary
antibodies at 4°C. All primary antibodies were incubated in 5%
bovine serum albumin (Sigma-Aldrich, St. Louis, MO, USA).
The membranes were washed 3 times to remove unbound
antibody and then incubated with a horseradish peroxidase-
conjugated secondary antibody for 1 hour at room temperature.
Membranes were treated with enhanced chemiluminescence
reagents according to the manufacturer’s protocol (GE
Healthcare Life Science, PA, USA). Primary antibodies
included anti-phospho-AKT (Ser473), anti-Akt, anti-phospho-
ERK (T202/Y204), anti-ERK, anti-phospho-S6 (S240/244), anti-
S6, anti-phospho-4E-BP1(S65) and anti-4E-BP1 (Cell
Targeting PI3K and MEK in Pancreatic Cancer
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Signaling Technology, Beverly, MA, USA). ImageJ (freeware)
was used to compare the density of the bands and finish the
densitometric analysis.
In vivo Studies
Nude mice, 4 or 5-weeks-old, were purchased from the
National Cancer Institute. They were acclimated for 1-2 weeks
before they were subjected to any experimental procedures.
BxPC-3 cells (1x106) were injected subcutaneously (s.c.) into
mouse flanks. Tumor volumes were measured in two
dimensions (length and width) with calipers prior to treatment
and twice a week once treatment was initiated. Mice were also
weighed at these times, and weight changes were calculated
by the following formulary: [1- (new weight/initial weight)] × 100.
Tumor sizes were calculated by the standard formula of Tumor
Size = Length x Width2 x 0.5. Mice that developed tumors
reaching 100-150 mm3 in size were randomized into the
following four groups with 8 mice in each group: vehicle,
GDC0941, AZD6244, or the combination treatment. Both drugs
were administered once or twice daily by oral gavage in a
volume of 10 ml/kg body weight. Drugs were dissolved in a
vehicle of 0.5% (w/v) methycellulose/0.2% Tween 20 for
administration. The PI3K inhibitor was delivered daily at a final
concentration of 50 mg/kg [14], while the MEK inhibitor was
administered twice daily at a final concentration of 25 mg/kg
[15]. Control animals were given an equivalent volume of 0.5%
methycellulose/0.2% Tween 20 only, twice daily by oral
gavage. The treatment duration was 18 days. If the mouse
tumor diameter became larger than 15 mm during treatment or
the mouse’s weight decreased by 20% compared to its initial
weight, the mouse would be euthanized by CO2 overdose. All
studies were carried out in accordance with the protocol
approved by the Washington University Institutional Animal
Care Facility (Protocol number: 20100114).
Statistical Analyses
Cell viability data were represented as the mean ± standard
deviation (SD). Cell apoptosis data and tumor growth
experiments were represented as the mean ± standard error of
the mean (s.e.m.). Kaplan-Meier curves were used for survival
analyses. Statistical comparisons were made using the ANOVA
(single factor) and t-test (paired two samples for means and
unpaired t-test), as indicated. A p value of < 0.05 was
considered statistically significant.
Results
Concurrent inhibition of PI3K and MEK has a
synergistic effect on pancreatic cancer cell lines
growth in vitro
To determine the anti-tumor activity of the PI3K and MEK
inhibitors alone and in combination in vitro, four pancreatic
cancer cell lines were selected for study. BxPC-3 is a KRAS
wild type pancreatic cancer cell line, while the other three cell
lines harbor the KRAS mutation. All four cell lines are not
known to carry either PI3K or BRAF mutations [21]. The anti-
proliferative effect of the PI3K or MEK inhibitor alone in
BxPC-3, MIA PaCa-2, PANC-1 and Capan-2 cells was
measured by Alamar Blue. Only the growth of BxPC-3 and MIA
PaCa-2 cells was affected by GDC0941. The concentrations of
GDC0941 resulting in 50% inhibition of cell viability (IC50) after
72 hours exposure were 376.4 nM in BxPC-3 cells and 754.6
nM in MIA PaCa-2 cells (Figure 1A). AZD6244 alone also
suppressed cell growth with an IC50 value of 599 nM and 375
nM in BxPC-3 and MIA PaCa-2 cells, respectively (Figure 1B).
The IC50 was not reached for PANC-1 and Capan-2 cells lines
and as a result, these were considered to be resistant cell
lines. We did observe a slight increase in PANC-1 cell growth
with GDC0941at 1nM, 10nM, and 100nM, but changes were
not statistically significant (control vs 1 nM, p=0.32, control vs
10 nM, p=0.17, control vs 100 nM, p=0.22). In addition, we
compared control vs 1 nM AZD6244 in PANC-1 and MIA
PaCa-2 cells, and no significant differences were observed
(p=0.20, p=0.64, respectively)
The anti-proliferative effect of combining a PI3K and MEK
inhibitor was measured in BxPC-3 and MIA PaCa-2 cells by
calculating the combination index (CI) according to the Chou-
Talalay method (20) using a fixed dose ratio. Both
GDC0941and AZD6244 were introduced to cell cultures at
0.25×, 0.5×, 1×, 2× and 4× their respective IC50s in the BxPC-3
Figure 1.  Cell viability effect of GDC0941 and AZD6244 in
BxPC-3, MIA PaCa-2, PANC-1 and Capan-2 pancreatic
cancer cell lines.  Cells were treated with varying
concentrations of GDC0941 (A) or AZD6244 (B) alone for 72
hours. Doses ranged from 1 nM to 10 µM.
doi: 10.1371/journal.pone.0077243.g001
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and MIA PaCa-2 cell lines. Cell growth in both cell lines was
markedly decreased following combination treatment at
multiple paired concentrations when compared with either
single agent alone. Data were evaluated to get the CI under the
corresponding effective dose (ED) in BxPC-3 and MIA PaCa-2
cell lines (Figure 2) by CalcuSyn software. For the BxPC-3 cell
line the following CI values were obtained: 0.4101 (ED50),
0.0112 (ED75) and 0.0003 (ED90). For the MIA PaCa-2 cell
line the CI values were 0.02052 (ED50), 0.0295 (ED75) and
0.0440 (ED95). The CI results suggested that GDC0941 and
AZD6244 worked synergistically to produce an anti-proliferative
effect in the BxPC-3 and MIA PaCa-2 cell lines (Figure 2A-B).
Interestingly, while GDC0941 or AZD6244 alone did not
impact PANC-1 and Capan-2 cell growth, administration of
these two drugs in combination mildly inhibited cell growth. Cell
growth was reduced to 71.4% and 67.0% in the PANC-1 and
Capan-2 cell lines, respectively, following administration of the
drugs in combination (p<0.05, combination compared to
untreated group or single agent alone) (Figure 2C-D).
Concurrent PI3K and MEK inhibition induce apoptosis
of pancreatic cancer cells lines in vitro
To determine the apoptotic effect of the combined therapy,
two different concentrations of GDC0941 and AZD6244 were
used alone and in combination. While the apoptosis rate of
BxPC-3 cells at baseline was 17.0%, it increased significantly
to 34.0% and 47.8% following administration of GDC0941 at
380 nM and 1,520 nM concentrations, respectively (p<0.05,
GDC0941 alone vs. untreated group). AZD6244 alone at 600
nM and 2,400 nM increased the apoptosis rate of BxPC-3 cells
to 26.5% and 27.2%, respectively (p<0.05, AZD6244 alone vs
untreated group). A combination of GDC0941 and AZD6244
resulted in a much higher rate of apoptosis in BxPC-3 cells
compared with the control group or inhibitor alone. The
combination of GDC0941 at 380 nM and AZD6244 at 600 nM
or the combination of GDC0941 at 1,520 nM and AZD6244 at
2,400 nM increased the BxPC-3 cell apoptosis rate to 63.3%
and 82.8% respectively (p<0.05, combination vs. untreated
group or single agent alone) (Figure 3A). The rate of apoptosis
at baseline in MIA PaCa-2 cells was 8.0%, and it rose to 17.4%
and 24.7% with GDC0941 administered at 400 nM and 1,600
nM concentrations, respectively (p<0.05, GDC0941 alone vs.
untreated group). AZD6244 alone at 200 nM or 800 nM
increased the apoptosis rate to 22.7% and 36.9%, respectively
(p<0.05, AZD6244 alone vs. untreated group). The combination
of GDC0941 at 400 nM and AZD6244 at 200 nM or the
combination of GDC0941 at 1,600 nM and AZD6244 at 800 nM
increased the MIA PaCa-2 apoptosis rate to 49.5% and 55.6%,
respectively, and this was a statistically significant difference
compared to the untreated group or single agent alone
(p<0.05) (Figure 3B). For resistant cell lines PANC-1 and
Capan-2, while neither agent alone had a significant impact on
apoptosis, the combination of the PI3K and MEK inhibitor
resulted in an apoptosis rate of 31.8% in PANC-1 cells; this
was statistically significant compared to a 14.0% apoptosis rate
in these cells without treatment or with a single inhibitor (p
<0.05) (Figure 3C). Combining GDC0941 and AZD6244 also
significantly increased the apoptosis rate in Capan-2 cells to
Figure 2.  Synergistic effects of GDC0941-AZD6244
combination therapy on cell viability and
proliferation.  BxPC-3 (A) and MIA PaCa-2 cells (B) were
treated with GDC0941 alone, AZD6244 alone or GDC0941-
AZD6244 in combination. Results were analyzed according to
the Chou-Talalay method [18]. The combination index (CI)
values were calculated by using CalcuSyn software. PANC-1
(C) and Capan-2 cell line (D) were treated with GDC0941 at
400 nM, AZD6244 at 200 nM or combination. * p value <0.05
compared with control or single agent alone.
doi: 10.1371/journal.pone.0077243.g002
Targeting PI3K and MEK in Pancreatic Cancer
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41.3%, compared to 12.2% without treatment or with single
agent alone (p <0.05) (Figure 3D).
Effects of PI3K and MEK inhibitions on cell signaling
To assess the impact of both drugs on downstream effectors
of the PI3K and MEK pathways, we used Western blot analysis
to observe total protein expression and phosphorylation status.
The total protein levels of ERK, S6 and 4E-BP1 remained
unchanged after treatment with GDC0941 and AZD6244 in
each cell lines (Figure 4). p-ERK, p-S6 and p-4E-BP1
appeared to be suppressed by GDC0941 and AZD6244
combination treatment. However, we observed changes in AKT
expression following combination drug treatments, and
densitometric analysis was used to quantify the expression
levels. We used the ratio of p-AKT/AKT produced from each
dose for comparison. After p-AKT/AKT levels of treatment
groups were normalized to the ratio of the untreated group, the
combination treatment was observed to suppress p-AKT levels
by 90% in the BxPC-3 cell line, by 6% in the MIAPaCa-2 cell
line, by 29% in the PANC-1 cell line, and by 8% in the Capan-2
cell line. The combination of both drugs reduced p-ERK (T202/
Y204), p-AKT (S473), p-S6 (S240/244) and p-4E-BP1 (S65)
expression compared with baseline in all cell lines tested.
While p-AKT and p-ERK levels were differentially expressed in
the four cell lines, our study showed that the baseline levels of
p-AKT did not predict response to the PI3K inhibitor, nor did
baseline p-ERK levels predict response to the MEK inhibitor.
To understand the phenotypic differences seen in the MIA
PaCa-2 (sensitive to GDC0491 and AZD6244) and PANC-1
(resistant to GDC0491 and AZD6244) cell lines, both of which
harbor the KRAS mutation, we examined the differences in
their downstream effectors following GDC0941 and AZD6244
administration (Figure 5). In both cell lines, GDC0941
suppressed phosphorylation of AKT, AZD6244 decreased p-
Figure 3.  Effects of GDC0941 and AZD6244 therapy on cell apoptosis in pancreatic cancer cell lines.  Pancreatic cancer cell
lines were treated with GDC0941 alone, AZD6244 alone or GDC0941-AZD6244 in combination for 72 hours. Cell apoptosis was
detected by flow cytometry. A, B: combinations vs. untreated groups (*p values <0.05), combinations vs. single agents (*p values
<0.05), single agents vs. untreated groups (*p values <0.05). C, D: combinations vs. untreated groups (*p value <0.05) and
combinations vs. single agents (*p value <0.05).
doi: 10.1371/journal.pone.0077243.g003
Targeting PI3K and MEK in Pancreatic Cancer
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ERK levels, and the combination of the two drugs suppressed
both p-AKT and p-ERK levels. GDC0941 and AZD6244 had a
similar effect on AKT and ERK in the two cell lines.
Interestingly, the impact from both inhibitors on p-S6 and p-4E-
BP1 levels was, alternatively, cell line specific. For example,
GDC0941 and AZD6244 alone and in combination markedly
inhibited p-S6 and p-4E-BP1expression levels in MIA PaCa-2
cells, compared with the minimal suppression observed in
PANC-1 cells (Figure 5). Neither GDC0941 nor AZD6244 alone
suppressed p-S6 and p-4E-BP1 in PANC-1 cells, suggesting
that both effectors may serve as biomarkers associated with
treatment response. The expression levels of p-S6 and p- 4E-
BP1 were significantly suppressed by the combination therapy
in MIA PaCa-2 cells, and this was consistent with the cell line’s
phenotypic responses toward combination treatment.
Anti-tumor Effects of PI3K and MEK inhibitions in vivo.
To detect the effect of GDC0941 and AZD6244 on tumor
growth in vivo, we used GDC0941, AZD6244, and a
combination of GDC0941and AZD6244 to treat BxPC-3
xenograft mice for 18 days. Compared to the control (vehicle)
group, tumor volumes decreased significantly in the AZD6244
and combination groups (p=0.037 and p=0.032, respectively)
but not in the GDC0941group as compared to control (Figure
6A). Based on the Kaplan-Meier curves (Figure 6B), there was
a statistically significance difference in survival among the four
groups (p=0.005).
Discussion
Although targeted therapy has become a mainstream
approach for cancer treatment, the clinical development of
targeted agents in pancreatic cancer has not been successful.
Because of the high frequency of KRAS mutations in
pancreatic cancer, KRAS has been directly targeted in pre-
clinical and clinical trials, but results have been disappointing.
In light of these challenges, research efforts have refocused on
targeting the KRAS downstream pathways, PI3K and MEK.
The benefit of blocking an individual pathway has been largely
limited by the presence of a compensatory feedback loop
between PI3K and MEK. For example, inhibition of the MEK
pathway results in activation of the PI3K pathway [11], and
Figure 4.  Effects of GDC0941-AZD6244 combination therapy on PI3K/AKT and MEK/ERK pathways.  All four pancreatic
cancer cell lines were treated with the GDC0941-AZD6244 combination for 24 hours, Cell lysates were then harvested to detect p-
AKT (S473)/AKT, p-ERK (T202/Y204)/ERK, p-S6 (S240/244)/S6 and p-4E-BP1 (S65)/4E-BP1.
doi: 10.1371/journal.pone.0077243.g004
Targeting PI3K and MEK in Pancreatic Cancer
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PI3K activation mediates resistance to MEK inhibition [22]. To
circumvent this compensatory feedback, concurrent blockade
of the two pathways has been tested, and synergy in anti-tumor
effects was detected, providing the rationale for phase I clinical
trials. Moreover, early signs of clinical benefit have been
reported in advanced cancer by a retrospective analysis on
patients receiving agents that target both pathways [23].
In contrast to work in other types of tumors, preclinical
evaluations of downregulating both pathways in pancreatic
cancer have been limited [19,24]. Our study is important in
several aspects. First, we have showed that the sensitivity of
pancreatic cancer cell lines toward either PI3K or MEK
inhibitors is not KRAS dependent. While differing in KRAS
status, BxPC-3 and MIA PaCa-2 cells have wild type PI3K and
PTEN, and both were sensitive to both inhibitors, which is
consistent with previously published reports [22,25]. Secondly,
our study showed that PI3K and MEK inhibition either alone or
in combination can induce apoptosis. In the past, drugs
targeting PI3K or MEK were thought to have more of a
cytostatic effect, but recent report suggests that this effect is
apoptotic [26] Thirdly, our study has demonstrated synergy in
suppression of cell growth and induction of apoptosis in two
sensitive cell lines (BxPC-3 and MIA PaCa-2) with the
combination regimen. Moreover, mild inhibition in cell growth
and induction of apoptosis were observed with the drug
combination in resistant cell lines (PANC-1 and Capan-2).
Although the degree of benefit from the combination treatment
was modest for both resistant cell lines, further understanding
of this benefit is warranted for this devastating disease. Our
study supports a similar preclinical study in pancreatic cancer
which showed that the treatment benefit of a MEK inhibitor was
enhanced by an AKT inhibitor [24].
A crucial element of targeted therapy development is to
determine molecular markers that predict the treatment
response. PI3K pathway alterations including HER2
amplification, PI3KCA mutations or PTEN loss have been
found to be associated with sensitivity to GDC0941 in breast
cancer cell lines in vitro and in vivo [27]; however, the above
genetic alternations are rarely present in pancreatic tumors
[21]. Our study suggests that downstream p-AKT suppressed
by GDC0941 does not predict cell sensitivity, nor does
downregulated p-ERK predict sensitivity to AZD6244. This
observation is consistent with previous reports [27].
To further understand the molecular events occurring after
concurrent blockade in both KRAS mutated cell lines, we
compared protein expression in the PANC-1 (resistant) and
MIA PaCa-2 (sensitive) cell lines. These two cell lines differ in
their phenotypic response to PI3K and ERK inhibitors, despite
Figure 5.  Effects of GDC0941 and AZD6244 on PI3K/AKT and MEK/ERK pathways of MIA PaCa-2 and PANC-1 cell
lines.  Both MIA PaCa-2 and PANC-1 cells were treated with 400 nm GDC0941, 200 nM AZD6244 or a combination at these doses
for 24 hours. Cell proteins were then harvested to detect p-AKT(S473)/AKT, p-ERK(T202/Y204)/ERK, p-S6(S240/244)/S6 and p-4E-
BP1(S65)/4E-BP-1.
doi: 10.1371/journal.pone.0077243.g005
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Figure 6.  Effects of GDC0941 and AZD6244 on BxPC-3
xenograft model.  A: 1×106 BxPC-3 pancreatic cancer cells
were injected s.c. into the right flank of female nude mice. Mice
received vehicle (0.5% methylcellulose /0.2% Tween-20), 50
mg/kg GDC0941 QD, 25 mg/kg AZD6244 BID, or 50 mg/kg
GDC0941 QD plus 25 mg/kg AZD6244 BID orally for 18 days.
Data are presented as mean ± SE. *p values were determined
by unpaired t-test. B: Kaplan-Meier survival curves of
xenografts receiving vehicle, GDC0941 alone, AZD6244 alone
and GDC0941-AZD6244 in combination.
doi: 10.1371/journal.pone.0077243.g006
harboring similar major genetic alternations. Both cell lines are
reported to contain KRAS mutations, p53 mutations, wild type
P16 and wild type DPC-4 [21]. While in our study we
demonstrated that suppression of p-AKT by the PI3K inhibitor
and p-ERK by the MEK inhibitor were achieved in both cell
lines, PANC-1 cells experienced only a minimal suppression of
p-S6 and p-4E-BP1 when treated with either the PI3K or MEK
inhibitor alone. These finding suggests that the PI3K or MEK
inhibitors alone are able to suppress their immediate
corresponding downstream mediators (AKT and ERK) in
PANC-1 cells, but are not able to downregulate the further
downstream mediators (p-S6 and p-4E-BP1). Both markers,
therefore, are closely associated with sensitivity to both PI3K
and MEK inhibitors. In a complex signaling network, a targeted
agent’s capacity to inhibit the phosphorylation process of its
downstream targets frequently does not translate into
phenotypical changes. For example, Serra et al have reported
the identification of a few genes which may promote cellular
survival in the context of PI3K blockade, and among those
genes, ribosomal S6 kinases RPS6KA2 (RSK3) and RPS6KA6
(RSK4) are being further validated for contributing to PI3K
resistance in vitro and in vivo through attenuation of the
apoptotic process and upregulation of protein translation [28].
Our observation resonates with emerging evidence that
downstream cap-dependent translation may be a better
indicator of response to these targeted agents [29,30].
4E-BP1 plays a major role in cap-dependent translation. It
binds to the elF4E-mRNA cap complex to inhibit cap-
dependent translation, and phosphorylated 4E-BP1 then falls
out of the translation complex, so initiation of translation can
begin [31]. mTORC1, an effector downstream of the PI3K
pathway, can phosphorylate 4E-BP1 to initiate the translation
process [32]. The crucial role of 4E-BP1 as a key effector of the
AKT and ERK signaling pathways in tumors has been elegantly
studied by She et al [29]. Moreover, high expression levels of
4E-BP1 have been found to have prognostic value in several
tumor types [33-37]. Therefore, further exploration of targeting
4E-BP1 should be explored in the future for multiple tumor
types, including, and especially, pancreatic cancer.
In summary, we have explored the benefit of concurrent
pathway blockade by PI3K and MEK inhibitors alone and in
combination for pancreatic cancer. Synergy in decreasing cell
growth was observed and the effects were not KRAS
dependent. Persistent phosphorylation of S6 and 4E-BP1
appeared to be associated with resistance to the PI3K and
MEK inhibitors. Future investigations into the alternative
mechanisms of 4E-BP1 phosphorylation and targeting of 4E-
BP1 in pancreatic cancer are warranted.
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